Musculoskeletal Cancers Clinical Trial
— REVENRIOfficial title:
Randomized, Monocentric, Controlled, Superiority Phase II Trial Evaluating Clinical Hypnosis Using Virtural Reality vs Standard Pain Management Procedure During a Musculoskelettal Biopsy
| Verified date | August 2018 |
| Source | Centre Leon Berard |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The primary objective of this trial is to evaluate the benefit of the virtual reality technology in the pain management for patients having a radio-guided musculoskeletal biopsy indication
| Status | Completed |
| Enrollment | 99 |
| Est. completion date | May 16, 2018 |
| Est. primary completion date | May 16, 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Man or woman, aged >= 18 years at the day of consenting to the study (no upper limit) - Requiring a radio-guided biopsy of the musculoskeletal system, - Informed and signed consent, - Patient covered by a medical insurance. Exclusion Criteria: - Deaf patient; - Visually-impaired patient; - Claustrophobic and/or aquaphobic patient; - Contraindication to a musculoskeletal biopsy, including to the premedication protocol and to the lidocaine; - Person deprived of liberty or placed under guardianship; - Absence of French language skills; - History of psychiatric disease such as paranoia, schizophrenia, manic-depressive psychosis, patient with a high risk of suicide. |
| Country | Name | City | State |
|---|---|---|---|
| France | Centre Leon Berard | Lyon |
| Lead Sponsor | Collaborator |
|---|---|
| Centre Leon Berard |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Evaluate the benefit of the virtual reality in the pain management of patients needing a radio-guided musculoskeletal biopsy. | The main outcome will be the pain level auto-evaluated by the patient using a numeric scale composed of 11 graduations (from 0 to 10) | Day 0 | |
| Secondary | Evaluate in both arms, the pain linked to the biopsy procedure using a numeric scale graduated from 0 to 10. | The score " 0 " corresponds to " No pain " and the score " 10 " corresponds to " Maximum amount of imaginable pain " | Day 1 (+/-2h) post biopsy | |
| Secondary | Evaluate in both arms, the anxiety linked to the biopsy procedure using a numeric scale graduated from 0 to 10 | The score " 0 " corresponds to " No anxiety " and the score " 10 " corresponds to " Maximum imaginable anxiety " | Day 0 | |
| Secondary | Evaluate the analgesics consumption in both arms | Evaluation according to the following classification and recording the dosages and units taken: Level 1 - Non morphinic analgesics; Level 2 - Weak opioides analgesics; Level 3 - Strong opioides analgesic | through study completion, an average of 24 hours | |
| Secondary | Evaluate the global satisfaction of patients in both arms | The score "0" corresponds to " Absence of satisfaction " and the score " 10 " corresponds to " Full satisfaction ". | Day 0 | |
| Secondary | Evaluate costs in both arms | Evaluation of costs involved for the patient's treatment and care | through study completion, an average of 24 hours |